Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,324 | 2,812 | 4,418 | 1,858 | 1,063 |
| Other current assets | 3 | 3 | 3 | 3 | 3 |
| TOTAL | $1,723 | $3,077 | $4,722 | $1,954 | $1,162 |
| Non-Current Assets | |||||
| PPE Net | 2 | 3 | 3 | 3 | 4 |
| TOTAL | $2 | $3 | $3 | $3 | $4 |
| Total Assets | $1,725 | $3,080 | $4,725 | $1,957 | $1,166 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 207 | 74 | 168 | 16 | 61 |
| Accrued Expenses | N/A | N/A | 212 | N/A | 150 |
| Other current liabilities | 14,057 | 11,030 | 28,332 | 15,923 | 11,111 |
| TOTAL | $14,264 | $11,103 | $28,712 | $15,939 | $11,321 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 3,864 | 3,618 | 3,878 | 1,580 | 0 |
| TOTAL | $3,864 | $3,618 | $3,878 | $1,580 | $N/A |
| Total Liabilities | $18,128 | $14,721 | $32,589 | $17,519 | $11,321 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 536 | 536 | 536 | 536 | 535 |
| Common Shares | 134 | 134 | 134 | 134 | 133 |
| Retained earnings | -37,025 | -32,094 | -48,000 | -33,225 | -27,003 |
| Other shareholders' equity | 0 | 0 | 2,014 | 0 | 983 |
| TOTAL | $-16,403 | $-11,641 | $-27,864 | $-15,562 | $-10,155 |
| Total Liabilities And Equity | $1,725 | $3,080 | $4,725 | $1,957 | $1,166 |